ArdentOnco
Regenerative oncology, thoughtfully advanced.
ArdentOnco is the research and clinical exploration arm of Ardent— pushing what’s possible in cancer care with regenerative science, careful design, and compassion.
ArdentOnco is the research and clinical exploration arm of Ardent— pushing what’s possible in cancer care with regenerative science, careful design, and compassion.
Our aim is simple: explore thoughtful, natural-leaning care —without overpromising, and without cutting corners.
Regenerative by Design
We investigate cell-derived and biologic approaches intended to work with the body.
Safety at the Center
Protocols are developed emphasizing oversight, quality, and comfort.
Precisely Measured
We move fast where it’s smart, and slow where it matters—keeping methods precise and data honest.
Clinical Trial
Autologous Cancer Vaccine + Checkpoint Modulator
A randomized trial for dogs with appendicular osteosarcoma, comparing a personalized vaccine made from the dog’s own tumor (K9-ACV) plus a novel immune modulator (CD200AR-L) to standard carboplatin chemotherapy.
Goal: Explore safety, practicality, and potential benefits of a regenerative, immune-based approach.
Eligibility: Dogs ≥1 yr, ≥20 kg, confirmed Stage IIB osteosarcoma, no recent chemo, radiation, or immune drugs.
Funding: Partially covered; owners typically cover surgery and unrelated care.
The ArdentOnco Team
Adrienne Wright, MBA, PHD
Site Leader VP, Science & Commercializaton
Dr. Tim Fan, DVM, PHD
Principal Investigator at University of Illinois
Dr. Brian Flesner DVM, MS, DACVIM (ONCOLOGY)
Project Manager
Marissa Kroll
Study Monitor
Delaney Kennedy
Operations and Customer Support Manager